Table 1 Regimens used as the third-line treatment
Regimen | All patients | Study cohort |
|---|---|---|
Erlotinib | 29 (48%)a | 28 (48%) |
Gefitinib | 1 (2%) | Â |
Chemotherapy without platinum: | ||
 Pemetrexed | 1 (2%) | 1 (2%) |
 Gemcitabine | 7 (12%) | 7 (12%) |
 Vinorelbine | 7 (12%) | 7 (12%) |
 Taxanes | 5 (8%) | 5 (9%) |
Platinum-based doublet: | ||
 Pemetrexed + Platinum | 4 (7%) | 4 (7%) |
 Gemcitabine + Platinum | 1 (2%) | 1 (2%) |
 Vinorelbine + Platinum | 2 (3%) | 2 (3%) |
 Taxanes + Platinum | 3 (5%) | 3 (5%) |
 Total | 60 | 58 |